Genentech was entering the MS market for the first time against Biogen, which had a significant market share, six products, and decades of established patient and HCP relationships. The digital campaign and associated social media community were designed to help the brand break through to patients already on MS therapy and influence their health support teams’ prescribing decisions.
Details
Role
The primary goal of the OCREVUS digital campaign was to rise above the crowded MS market, particularly with entrenched neurologist prescribers. Inspirational patient stories, strong clinical data, and aspirational messaging set the stage for a radical new therapy option for patients living with the disease.
The core campaign promise, “Have fewer maybes with OCREVUS,” carried over from the print brand campaign, featuring product information and unique clinical experiences through authentic lifestyle and inspirational content. An infographic style highlighting OCREVUS’ product benefits made it easier to differentiate from other branded MS content.
Research showed that the brand had to engage in channels where people with MS were looking for new treatment options. With MS Voice already building momentum, extending the OCREVUS digital campaign into Genentech’s first branded Facebook community was a strategically sound way to keep building awareness and trust.
Rounding out the social mix, YouTube hosted patient and physician videos that explored the treatment journey in greater depth and explained how to set patients and their care teams up for success once they were on therapy.